Beijing Med-Pharm Announces Hire of Wang Bingyu as Vice President Sales & Marketing of its Chinese Operations
Plymouth Meeting, PA, August 8, 2005 - Beijing Med-Pharm Corp. (BJGP.PK) today announced that Wang Bingyu has been hired as the Vice President, Sales and Marketing of its Chinese division, Beijing Med-Pharm Co., Ltd.
Mr. Wang, a Beijing native and accomplished pharmaceutical executive, will be responsible for implementing the Company's sales and marketing strategy in China, developing solutions for US and European pharmaceutical firms interested in entering the Chinese marketplace.
Mr. Wang most recently spent five years as Director, Sales and Marketing for Sino-American Beijing HuaJin Pharmaceuticals Co. Ltd. At HuaJin, Mr. Wang managed a 130-person sales and marketing team and was responsible for developing the company's marketing budget as well as executing its sales and marketing strategy. Product categories under his purview included diabetes, cardiovascular, and antibiotics.
Prior to HuaJin, Mr. Wang's experience includes serving three years as a Senior Product Manager at Pfizer Pharmaceuticals in Beijing.
Prior to Pfizer, Mr. Wang spent three years as a Regional Sales Manager at Sino-America Shanghai Squibb Pharmaceutical Ltd. in Beijing. In this position, Mr. Wang helped the company to penetrate new markets including Harbin, Shijiazhuang, and Taiyuan; Mr. Wang also aided the company in registering two products (Fusinopril and Provastatin) with the Chinese SFDA and launching two new products (Provastatin and Azactum) in Beijing.
Prior to Squibb, Mr. Wang was the Physician in Charge of the Thoracic Surgery Department at the Beijing Anzhen Hospital.
"Bingyu brings to Beijing Med-Pharm tremendous accomplishment in developing Chinese sales and marketing programs for some of the world's top pharmaceutical companies," says David Gao, CEO of Beijing Med-Pharm.
"Add to this his training as a physician, his management experience, and his overall business acumen, and we believe Mr. Wang will strengthen Beijing Med-Pharm's ability to serve companies aspiring to enter this large and growing pharmaceutical marketplace."
Mr. Wang earned a MBA from Massey University in New Zealand; a Master of Medicine degree from the Beijing Heart Lung and Blood Vessel Medical Center; and a Bachelor of Medicine degree from the Nanjing Railway Medical College.
For further information please contact
Beijing Med-Pharm
Ben Austin
+1 (917) 686 3979
baustin@beijingmedpharm.com
Amphion Innovations plc
Josh Berkman, Media Relations
+1 (646) 747 7158
About Beijing Med-Pharm
Beijing Med-Pharm helps U.S. and European pharmaceutical companies wishing to enter the Chinese market. Beijing Med-Pharm offers an array of services designed to establish a market for western pharmaceuticals and to fulfill that market through a comprehensive distribution plan. Beijing Med-Pharm is a US-managed and US-listed company, traded on the Pink Sheets as (BJGP.PK).
On the web: www.beijingmedpharm.com
About Amphion Innovations plc
Amphion Innovations plc recently listed on the AIM Exchange in London under the symbol AMP.L. Amphion's business is the formation, financing, management, and development of life science and technology companies, working in partnership with corporations, governments, universities, and entrepreneurs seeking to commercialize their intellectual property.
On the web: www.amphionplc.com
